Somanta Pharmaceuticals is Pharmaceuticals in United States that focus on monoclonal antibody business. Founded in 2001. They cover business area such as developer, biotechnology drug, cancer treatment, Angiolix, cell death, apoptosis, blood vessel, tumor, a molecule, normally oxygenate healthy tissue, its toxic form, various phase, DNA, Deoxyribonucleic acid, dna processing enzyme.
2001
( 23 years old in 2024 )
Monoclonal Antibody
-
19200 Von Karman Avenue
Suite 400
Irvine, CA 92612
United States
Private
developerbiotechnology drugcancer treatmentAngiolixcell deathapoptosisblood vesseltumora moleculenormally oxygenate healthy tissueits toxic formvarious phaseDNADeoxyribonucleic aciddna processing enzyme
* We use standard office opening hours in near Somanta Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Somanta Pharmaceuticals is Pharmaceuticals business from United States that founded in 2001 (23 years old in 2024), Somanta Pharmaceuticals business is focusing on Monoclonal Antibody.
Somanta Pharmaceuticals headquarter office and corporate office address is located in 19200 Von Karman Avenue Suite 400 Irvine, CA 92612 United States.
Somanta Pharmaceuticals was founded in United States.
In 2024, Somanta Pharmaceuticals is currently focus on monoclonal antibody sector.
Above is snippet of Google Trends for "monoclonal antibody" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Somanta Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
